MRI-guided radiotherapy for rectal cancer treatment
Total Neoadjuvant Treatment of Rectal Cancer by MRI-guided Radiotherapy: a Prospective Observational Study
This study is testing a new type of targeted radiation therapy for people with locally advanced rectal cancer to see if it helps them respond better to treatment and live healthier lives.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Jette, Brussels Capital) |
| Trial ID | NCT05916040 on ClinicalTrials.gov |
What this trial studies
The TNTRect trial is a prospective observational study aimed at evaluating the effectiveness of MR-guided stereotactic body radiotherapy (SBRT) for patients with locally advanced rectal cancer. Participants will receive a hypofractionated treatment consisting of 5 daily sessions of 5 Gy, with a simultaneous integrated boost to the tumor. The study will assess patient responses through endoscopy, MRI, and pathology reports, while also measuring local control, disease-free survival, overall survival, and quality of life. The goal is to enhance the complete clinical response rate and promote organ-preserving treatment options.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with locally advanced rectal cancer who are fit for radiotherapy.
Not a fit: Patients with unresectable metastatic disease or poor performance status may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved treatment outcomes and organ preservation for patients with rectal cancer.
How similar studies have performed: While this approach is innovative, similar studies using MR-guided radiotherapy have shown promising results in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Locally advanced rectal cancer Exclusion Criteria: * Patients with unresectable metastatic disease at diagnosis * Patients with an ECOG performance status \> 2 * Patients not deemed fit for radiotherapy, chemotherapy or surgery
Where this trial is running
Jette, Brussels Capital
- UZ Brussel - Dienst Radiotherapie — Jette, Brussels Capital, Belgium (Recruiting)
Study contacts
- Principal investigator: Mark De Ridder, MD — Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel
- Study coordinator: Mark De Ridder, MD
- Email: mark.deridder@uzbrussel.be
- Phone: 00324776041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.